Open Orphan PLC represents values of innovation, collaboration, and scientific expertise in the field of human challenge studies and viral services. The company is dedicated to accelerating the development of new treatments and vaccines through its state-of-the-art facilities and expert team. With a strong focus on patient safety and ethical conduct, Open Orphan PLC strives to provide the highest quality data and insights for its clients. By combining cutting-edge research with a collaborative approach, the company aims to transform the way infectious diseases are understood and ultimately contribute to global health security.

Open Orphan PLC primarily operates in the United Kingdom and Ireland.

Open Orphan PLC has achieved several significant milestones. The company successfully completed the reverse acquisition of hVIVO Group PLC in 2019, thereby expanding its expertise in viral challenge studies and immunology. Open Orphan also acquired Venn Life Sciences in 2020, strengthening its position as a leading European pharmaceutical services company. The company has secured numerous contracts with major pharmaceutical companies and government organizations for the provision of clinical research services. Open Orphan has further enhanced its capabilities by establishing a unique, industry-leading data platform, helping clients expedite their drug development processes. These achievements highlight Open Orphan PLC's commitment to advancing pharmaceutical research and its growing presence in the industry.

Open Orphan PLC is a leading clinical research organization (CRO) specializing in orphan drugs and rare diseases. Founded in 2017, Open Orphan has emerged as a trusted partner for pharmaceutical companies, academic institutions, and government bodies. With a focus on providing innovative solutions, Open Orphan offers a range of services including clinical trial management, data management, biostatistics, and regulatory affairs. The company's expertise promotes the development of treatments for rare diseases, ultimately improving patient outcomes. Open Orphan PLC's dedication to advancing medical research and tackling unmet medical needs has positioned it as a prominent player in the biopharmaceutical industry.

The main competitors of Open Orphan PLC in the market are pharmaceutical companies such as Covance Inc., Medpace Holdings, Inc., and Proclinical Group Ltd. These companies operate in the same industry and offer similar services and solutions in the areas of clinical research, drug development, and contract research organization (CRO) services. However, Open Orphan PLC distinguishes itself by its focus on orphan drugs and rare diseases, which sets it apart from its competitors and allows for a niche market position.

Open Orphan PLC is primarily active in the pharmaceutical industry.

Open Orphan PLC is a clinical research organization (CRO) specializing in orphan drugs, a lucrative market segment. The company offers a unique business model that focuses on providing clinical solutions and orphan drug consultancy services. Open Orphan PLC collaborates with pharmaceutical companies, biotechs, and academic institutions to develop and commercialize treatments for rare diseases. By leveraging their expertise in orphan drugs, clinical trial management, and data analytics, Open Orphan PLC aims to accelerate the development of innovative therapies and ultimately improve patient outcomes. With a strong emphasis on research and development, the company is committed to addressing unmet medical needs in the orphan drug space.

Pašreizējais KGV hVIVO nevar tikt aprēķināts.

KUV šobrīd hVIVO nevar aprēķināt.

AlleAktien kvalitātes vērtējums hVIVO ir 6/10.

gaidāmā hVIVO apgrozījums ir 69,93 milj. GBP.

gaidāmā hVIVO peļņa ir 11,88 milj. GBP.

The company Open Orphan PLC is an emerging company in the field of clinical research and development. The company specializes in conducting phase I and phase II studies for new drugs and vaccines. Its goal is to improve healthcare through the discovery and development of new therapies and remedies. Open Orphan's business model includes three main areas: clinical research, vaccine development, and therapeutics development. In clinical research, the company collaborates with pharmaceutical and biotechnology companies to conduct clinical trials. Open Orphan offers comprehensive services ranging from study planning to data analysis. In the field of vaccine development, Open Orphan works closely with its clients to develop vaccines for various diseases. The company has extensive expertise in developing vaccines for both infectious and non-infectious diseases. Clients of Open Orphan benefit from its expertise and modern technology to bring their vaccines from development to market approval. Furthermore, Open Orphan also develops therapeutics for various diseases. The company specializes in developing innovative therapies for rare and difficult-to-treat diseases. Its aim is to improve the quality of life for patients and provide them with better treatment options. Open Orphan emphasizes close collaboration with customers, partners, suppliers, and scientists in all its activities. The company aims to strengthen its scientific expertise by collaborating with leading research institutions and scientists to achieve the best results. The company also prioritizes maintaining high transparency regarding clinical data and study results. The goal is to improve public health through the improvement of medical research and development. With its innovative technologies, comprehensive expertise, and experienced employees, Open Orphan has already achieved a strong position in clinical research and development. Overall, Open Orphan's business model is focused on helping pharmaceutical companies and research institutions discover, develop, and bring new and innovative therapies and vaccines to the market. This is achieved through close collaboration with partners, the use of modern technologies, and the goal of improving public health.

hVIVO izmaksā dividendes 0 GBP, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt hVIVO vai uzņēmums nedod dividendes.

hVIVO ISIN ir GB00B9275X97.

hVIVO WKN ir A1KAME.

hVIVO simbols ir HVO.L.

Pēdējo 12 mēnešu laikā hVIVO maksāja dividendes 0,00 GBP apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos hVIVO plāno maksāt dividendes 0,00 GBP apmērā.

hVIVO pašreizējā dividendu rentabilitāte ir .

hVIVO maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

hVIVO pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0,00 GBP. Tas atbilst dividendes ražībai 1,06 %.

hVIVO tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu hVIVO apmērā 0,002 GBP, kas tika izmaksāta 20.05.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 18.04.2024..

Pēdējās dividendes izmaksa notika 20.05.2024..

Gadā 2024, hVIVO izmaksāja 0,005 GBP dividendes.

hVIVO dividendes tiek izmaksātas GBP.